Comparative Pharmacology
Head-to-head clinical analysis: EPANED versus VASOSTRICT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPANED versus VASOSTRICT.
EPANED vs VASOSTRICT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epaned contains enalapril maleate, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is a prodrug that is hydrolyzed to enalaprilat, which inhibits ACE, thereby reducing angiotensin II formation, decreasing vasoconstriction, aldosterone secretion, and sodium reabsorption.
Vasopressin is a synthetic analogue of the antidiuretic hormone (ADH) that acts on V1 receptors (vascular smooth muscle) to cause vasoconstriction, and on V2 receptors (renal collecting ducts) to increase water reabsorption. At high doses used in vasodilatory shock, it primarily increases systemic vascular resistance via V1 receptor activation.
0.2 mg/kg intravenously over 5 minutes every 2 hours; typical adult dose 10-20 mg IV.
0.01-0.03 units/min IV continuous infusion, titrate to effect. Maximum 0.1 units/min.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 10-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and 15-20 hours in severe impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 10–20 minutes, with clinical effect terminated rapidly by enzymatic degradation (catechol-O-methyltransferase and monoamine oxidase) in the liver and other tissues.
Renal excretion of unchanged drug accounts for approximately 30-40% of elimination; biliary/fecal excretion accounts for 50-60% as metabolites and unchanged drug.
Primarily renal (90–95% as inactive metabolites); minor biliary/fecal excretion (<5%).
Category C
Category C
Vasopressor
Vasopressor